In depth

Summary of the phase 3 trials investigating the IL-17A/IL-17F inhibitor bimekizumab in patients with ankylosing spondylitis, nonradiographic axial spondyloarthritis, or psoriatic arthritis.

Zachary Wallace discusses the changes that have occurred in rheumatology practice as a result of the COVID-19 pandemic, and explores what lessons can be taken forward to improve patient care.

Peter Nash discusses the latest evidence on the association between JAK inhibitors and the risk for VTE, MACE, and malignancy

Expert opinions differ on whether regulatory recommendations should be changed in light of the FAST trial results

With COVID-19 vaccination programs underway in many countries, we answer some of the key questions rheumatologists may have, drawing on recommendations from the main professional organizations.

We talk to the experts about the increasing use of telemedicine in rheumatology during the COVID-19 pandemic, exploring what needs to be considered for different rheumatic diseases and whether telerheumatology is here to stay.

Eric Morand explores the reasons why the TULIP-1 and TULIP-2 trials of anifrolumab found different primary results, and discusses the search for optimal endpoints in lupus trials.

Sharon Kolasinski talks about what’s new in the latest ACR–Arthritis Foundation recommendations for the management of osteoarthritis, and highlights the key take-home messages for healthcare providers.

A quick-reference guide to the phase 3 trials of the IL-17A inhibitors secukinumab and ixekizumab in patients with psoriatic arthritis.

Christopher Edwards discusses the latest evidence and shares his opinion on tapering therapy in patients with rheumatoid arthritis.

Michael Ward talks about what’s new in the updated US guidelines for the management of ankylosing spondylitis and nonradiographic axial spondyloarthritis.

A quick-reference guide to the phase 3 trials of IL-17A inhibitors for the treatment of ankylosing spondylitis.

Roy Fleischmann puts the new FDA boxed warning of increased pulmonary embolism and death risk with tofacitinib into context for rheumatologists and their patients.

medwireNews talks to Walter Maksymowych and Marina Magrey about the impact of the recent FDA approval of certolizumab pegol for nonradiographic axial spondyloarthritis, and why the approval happened so much later in the USA than in Europe.

Laura Coates talks to medwireNews about the latest ACR/NPF guidelines for managing psoriatic arthritis, discussing the evidence supporting the recommendations and how they compare with others.

Antonis Fanouriakis, lead author of the updated EULAR guidelines for the management of lupus, talks to medwireNews about what’s new in these guidelines and how they will influence clinical practice.

medwireNews summarizes the completed and ongoing phase 3 trials of JAK inhibitors in patients with rheumatoid arthritis.

Dafna Gladman speaks to medwireNews about the trial data supporting the use of Janus kinase inhibitors in patients with psoriatic arthritis, and discusses the impact these agents may have.

medwireNews rounds up the completed and ongoing clinical trials investigating JAK inhibitors in patients with spondyloarthritis.